enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
Company profile
Ticker
ENTA
Exchange
Website
CEO
Jay Luly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Enanta Pharmaceuticals Security Corporation ...
ENTA stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
12 Mar 24
EFFECT
Notice of effectiveness
9 Feb 24
10-Q
2024 Q1
Quarterly report
8 Feb 24
8-K
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024
7 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
ARS
2023 FY
Annual report to shareholders
26 Jan 24
DEFA14A
Additional proxy soliciting materials
26 Jan 24
DEF 14A
Definitive proxy
26 Jan 24
8-K
Departure of Directors or Certain Officers
26 Dec 23
UPLOAD
Letter from SEC
27 Nov 23
Transcripts
ENTA
Earnings call transcript
2024 Q1
7 Feb 24
ENTA
Earnings call transcript
2023 Q4
20 Nov 23
ENTA
Earnings call transcript
2023 Q3
7 Aug 23
ENTA
Earnings call transcript
2023 Q2
8 May 23
ENTA
Earnings call transcript
2023 Q1
7 Feb 23
ENTA
Earnings call transcript
2022 Q4
21 Nov 22
ENTA
Earnings call transcript
2022 Q3
9 Aug 22
ENTA
Earnings call transcript
2022 Q2
10 May 22
ENTA
Earnings call transcript
2022 Q1
9 Feb 22
ENTA
Earnings call transcript
2021 Q4
23 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 85.39 mm | 85.39 mm | 85.39 mm | 85.39 mm | 85.39 mm | 85.39 mm |
Cash burn (monthly) | 3.26 mm | (no burn) | 10.34 mm | 11.43 mm | 7.20 mm | 8.60 mm |
Cash used (since last report) | 21.75 mm | n/a | 68.94 mm | 76.21 mm | 47.99 mm | 57.29 mm |
Cash remaining | 63.64 mm | n/a | 16.45 mm | 9.18 mm | 37.39 mm | 28.09 mm |
Runway (months of cash) | 19.5 | n/a | 1.6 | 0.8 | 5.2 | 3.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 130 |
Opened positions | 25 |
Closed positions | 26 |
Increased positions | 45 |
Reduced positions | 43 |
13F shares | Current |
---|---|
Total value | 214.13 bn |
Total shares | 21.48 mm |
Total puts | 1.50 k |
Total calls | 800.00 |
Total put/call ratio | 1.9 |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 2.10 mm | $23.46 bn |
BLK Blackrock | 1.98 mm | $22.11 bn |
Farallon Capital Management | 1.88 mm | $20.94 bn |
Vanguard | 1.66 mm | $18.55 bn |
Farallon Capital Partners | 1.46 mm | $0.00 |
Braidwell | 1.04 mm | $11.60 bn |
Millennium Management | 1.02 mm | $11.43 bn |
NTRS Northern Trust | 959.91 k | $10.72 bn |
Krensavage Asset Management | 735.10 k | $8.18 bn |
Assenagon Asset Management | 631.63 k | $7.06 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Lesley Russell | Stock Option Common Stock | Grant | Acquire A | No | No | 15.66 | 15,700 | 245.86 k | 15,700 |
6 Mar 24 | Kristine Peterson | Stock Option Common Stock | Grant | Acquire A | No | No | 15.66 | 15,700 | 245.86 k | 15,700 |
6 Mar 24 | Terry Vance | Stock Option Common Stock | Grant | Acquire A | No | No | 15.66 | 15,700 | 245.86 k | 15,700 |
6 Mar 24 | Hata Yujiro S | Stock Option Common Stock | Grant | Acquire A | No | No | 15.66 | 15,700 | 245.86 k | 15,700 |
6 Mar 24 | Mark G Foletta | Stock Option Common Stock | Grant | Acquire A | No | No | 15.66 | 15,700 | 245.86 k | 15,700 |
News
JP Morgan Maintains Underweight on Enanta Pharma, Lowers Price Target to $11
8 Feb 24
Recap: Enanta Pharma Q1 Earnings
7 Feb 24
Enanta Pharma Q1 2024 GAAP EPS $(1.58) Misses $(1.23) Estimate, Sales $18.00M Miss $21.95M Estimate
7 Feb 24
Earnings Scheduled For February 7, 2024
7 Feb 24
Earnings Preview For Enanta Pharma
6 Feb 24
Press releases
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
17 Apr 24
Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
6 Mar 24
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET
7 Feb 24
Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
6 Feb 24
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023
31 Jan 24